Status and phase
Conditions
Treatments
About
This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.
Full description
Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
You may be eligible if you:
Exclusion Criteria
You will not be eligible if you:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal